Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.

Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH.

Intervirology. 2006;49(3):144-51.

PMID:
16428890
2.

Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM.

Immunology. 2004 Oct;113(2):212-23.

3.

Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors.

Lau CK, Bayly CI, Gauthier JY, Li CS, Therien M, Asante-Appiah E, Cromlish W, Boie Y, Forghani F, Desmarais S, Wang Q, Skorey K, Waddleton D, Payette P, Ramachandran C, Kennedy BP, Scapin G.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):1043-8.

PMID:
15013020
4.

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM.

Eur J Immunol. 2004 Jan;34(1):251-62.

5.

History of vaccines and positioning of current trends.

Payette PJ, Davis HL.

Curr Drug Targets Infect Disord. 2001 Nov;1(3):241-7.

PMID:
12455398
6.

DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice.

Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL.

Vaccine. 2002 Sep 10;20(27-28):3263-71.

PMID:
12213395
7.

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.

FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85.

8.

Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics.

Jia Z, Ye Q, Dinaut AN, Wang Q, Waddleton D, Payette P, Ramachandran C, Kennedy B, Hum G, Taylor SD.

J Med Chem. 2001 Dec 20;44(26):4584-94.

PMID:
11741477
9.

The potential of CpG oligodeoxynucleotides as mucosal adjuvants.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.

Crit Rev Immunol. 2001;21(1-3):103-20. Review.

PMID:
11642598
10.

Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms.

Payette PJ, Weeratna RD, McCluskie MJ, Davis HL.

Gene Ther. 2001 Sep;8(18):1395-400.

11.

The use of CpG DNA as a mucosal vaccine adjuvant.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.

Curr Opin Investig Drugs. 2001 Jan;2(1):35-9. Review.

PMID:
11527008
12.

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.

Malanchère-Brès E, Payette PJ, Mancini M, Tiollais P, Davis HL, Michel ML.

J Virol. 2001 Jul;75(14):6482-91.

13.

The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase.

Asante-Appiah E, Ball K, Bateman K, Skorey K, Friesen R, Desponts C, Payette P, Bayly C, Zamboni R, Scapin G, Ramachandran C, Kennedy BP.

J Biol Chem. 2001 Jul 13;276(28):26036-43. Epub 2001 May 14.

14.

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, Davis HL, Emerson SU, Purcell RH, Bukh J.

Hepatology. 2000 Sep;32(3):618-25.

PMID:
10960458
15.

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM.

J Immunol. 2000 Feb 1;164(3):1617-24.

16.

Development and validation of an intact cell assay for protein tyrosine phosphatases using recombinant baculoviruses.

Cromlish WA, Payette P, Kennedy BP.

Biochem Pharmacol. 1999 Nov 15;58(10):1539-46.

PMID:
10535744
17.

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.

Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP.

Science. 1999 Mar 5;283(5407):1544-8.

18.

Refinement of an in vitro cell model for cytochrome P450 induction.

Silva JM, Morin PE, Day SH, Kennedy BP, Payette P, Rushmore T, Yergey JA, Nicoll-Griffith DA.

Drug Metab Dispos. 1998 May;26(5):490-6.

PMID:
9571231
19.

Development of an enzyme-linked immunosorbent assay for measurement of serum-associated ALX40-4C.

Payette PJ, Cormier M, Dabek B, Yungblut P, Presseault S, Climie S, Sahai J, Cameron WD, Filion LG.

Clin Diagn Lab Immunol. 1997 Nov;4(6):671-5.

20.

Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate.

Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B, Tsaprailis G, Gresser MJ, Ramachandran C.

J Biol Chem. 1997 Jan 10;272(2):843-51.

21.

Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2.

Huang Z, Payette P, Abdullah K, Cromlish WA, Kennedy BP.

Biochemistry. 1996 Mar 26;35(12):3712-21.

PMID:
8619991
22.

A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains.

Kennedy BP, Payette P, Mudgett J, Vadas P, Pruzanski W, Kwan M, Tang C, Rancourt DE, Cromlish WA.

J Biol Chem. 1995 Sep 22;270(38):22378-85.

23.

Human cytosolic phospholipase A2 expressed in insect cells is extensively phosphorylated on Ser-505.

Abdullah K, Cromlish WA, Payette P, Laliberté F, Huang Z, Street I, Kennedy BP.

Biochim Biophys Acta. 1995 May 11;1244(1):157-64.

PMID:
7766652
24.

Selective inhibitors of COX-2.

O'Neill GP, Kennedy BP, Mancini JA, Kargman S, Ouellet M, Yergey J, Falgueyret JP, Cromlish WA, Payette P, Chan CC, et al.

Agents Actions Suppl. 1995;46:159-68. Review.

PMID:
7610986
25.

High-level expression of active human cyclooxygenase-2 in insect cells.

Cromlish WA, Payette P, Culp SA, Ouellet M, Percival MD, Kennedy BP.

Arch Biochem Biophys. 1994 Oct;314(1):193-9.

PMID:
7944394
26.

Humor in a hospital--that's a laugh.

Payette P.

Ky Hosp Mag. 1993 Spring;10(2):14-6. No abstract available.

PMID:
10125440
27.

Vasocontractile muscarinic M1 receptors in cat cerebral arteries: pharmacological identification and detection of mRNA.

Dauphin F, Ting V, Payette P, Dennis M, Hamel E.

Eur J Pharmacol. 1991 Aug 14;207(4):319-27.

PMID:
1783002
28.

Expression and pharmacological characterization of the human M1 muscarinic receptor in Saccharomyces cerevisiae.

Payette P, Gossard F, Whiteway M, Dennis M.

FEBS Lett. 1990 Jun 18;266(1-2):21-5.

29.

[3H]U69,593 binding in guinea-pig brain: comparison with [3H]ethylketazocine binding at the kappa-opioid sites.

Tiberi M, Payette P, Mongeau R, Magnan J.

Can J Physiol Pharmacol. 1988 Nov;66(11):1368-72.

PMID:
2853991
30.

[On the issue of stress in police work.].

Payette P.

Sante Ment Que. 1985;10(2):140-4. French.

PMID:
17093523

Supplemental Content

Loading ...
Support Center